Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Similarity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44294   clinical trials with a EudraCT protocol, of which   7351   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Similarity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-003106-24 Sponsor Protocol Number: 721103 Start Date*: 2011-10-06
    Sponsor Name:Baxter Innovations GmbH
    Full Title: Effectiveness of PREFLUCEL vaccination against infection with seasonal influenza virus in an adult and elderly population aged 50 years and older
    Medical condition: To verify the effectiveness of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2011/2012 and 2012/2013 season respectively, manufactured us...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001505-90 Sponsor Protocol Number: 18CH049 Start Date*: 2018-10-01
    Sponsor Name:CHU de Saint Etienne
    Full Title: Decolonization of patients carrying S. aureus before cardiac surgery: study of the risk factors associated with failure
    Medical condition: Decolonization of S. aureus nasal carriers before cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10075981 Staphylococcus aureus infection LLT
    20.0 100000004865 10048935 Open heart surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005071-40 Sponsor Protocol Number: AVT03-GL-C01 Start Date*: 2022-10-31
    Sponsor Name:Alvotech Swiss AG
    Full Title: A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopa...
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002894-48 Sponsor Protocol Number: 1301.1 Start Date*: 2012-09-14
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, ac...
    Medical condition: Moderately to severely active Rheumatoid Arthritis that has had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) PT (Prematurely Ended) NL (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) NO (Prematurely Ended) GR (Completed) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003420-46 Sponsor Protocol Number: MYL-1410A-3001 Start Date*: 2015-07-22
    Sponsor Name:Mylan GmbH (Mylan)
    Full Title: Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Mode...
    Medical condition: Chronic Plaque-Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003287-37 Sponsor Protocol Number: EMR200588-002 Start Date*: 2016-03-15
    Sponsor Name:Merck KGaA
    Full Title: A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chro...
    Medical condition: moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-005543-90 Sponsor Protocol Number: 20130108 Start Date*: 2014-08-26
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) PL (Completed) BG (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022529-14 Sponsor Protocol Number: WC25501 Start Date*: 2011-02-04
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in pa...
    Medical condition: Coronary Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) NL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2006-002055-32 Sponsor Protocol Number: PSD506-OAB-004 Start Date*: 2006-10-09
    Sponsor Name:Plethora Solutions Limited
    Full Title: A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruct...
    Medical condition: This study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in li...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055026 Prostatic obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) IE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001638-12 Sponsor Protocol Number: mRNA-1010-P302 Start Date*: 2022-09-29
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older.
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) EE (Completed) BG (Completed) DK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002254-20 Sponsor Protocol Number: 1297.9 Start Date*: 2017-08-04
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm,...
    Medical condition: moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002283-41 Sponsor Protocol Number: 151032-002 Start Date*: 2017-09-11
    Sponsor Name:HRA Pharma
    Full Title: A prospective, randomized, parallel-group study to assess the effects on ovarian activity of ellaOne (ulipristal acetate 30 mg single dose) taken after three consecutive days of missed combined ora...
    Medical condition: Emergency contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002765-34 Sponsor Protocol Number: MabionCD20-003RA Start Date*: 2021-10-21
    Sponsor Name:Mabion S.A.
    Full Title: A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20 (manufactured in commercial scale), EU-approved MabThera® and US-licen...
    Medical condition: Moderate-to-severe rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000695-19 Sponsor Protocol Number: SB5-4001 Start Date*: 2022-07-22
    Sponsor Name:Samsung Bioepis Co., Ltd
    Full Title: A Phase IV, Randomised, Double-blind, Parallel-group, Multiple-dose, Active Comparator, Multicentre Clinical Study to Evaluate the Pharmacokonetics, Efficacy, Safety, and Immunogenicity of SB5 Vers...
    Medical condition: Moderate to severe plaque psioriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000542-18 Sponsor Protocol Number: 20200497 Start Date*: 2021-12-21
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With ...
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-004532-18 Sponsor Protocol Number: M10-239 Start Date*: 2014-11-12
    Sponsor Name:Abbott
    Full Title: A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
    Medical condition: Ankylosing Spondylitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004558-33 Sponsor Protocol Number: M10-240 Start Date*: 2014-12-09
    Sponsor Name:Abbott Japan Co., Ltd.
    Full Title: A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis
    Medical condition: Juvenile Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-002336-31 Sponsor Protocol Number: CT-P17-3.3 Start Date*: 2022-10-20
    Sponsor Name:CELLTRION, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005588-28 Sponsor Protocol Number: 000080 Start Date*: 2013-06-04
    Sponsor Name:Ferring International Pharmascience Center US, Inc.
    Full Title: A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Follo...
    Medical condition: Chronic idiopathic constipation
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10072118 Chronic idiopathic constipation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Completed) SK (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002930-19 Sponsor Protocol Number: XBR1001 Start Date*: 2019-02-25
    Sponsor Name:Xbrane Biopharma
    Full Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
    Medical condition: Wet Age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) HU (Completed) SK (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA